

Innate immunity protein IFITM3 modulates γ -secretase in Alzheimer disease

Ji-Yeun Hur^{1,ξ}, Georgia R. Frost^{1,2,ξ}, Xianzhong Wu¹, Christina Crump^{1,3}, Si Jia Pan¹, Eitan Wong¹, Marilia Barros¹, Thomas Li^{1,2}, Pengju Nie^{1,3}, Yujia Zhai¹, Jen Chyong Wang⁴, Julia TCW⁴, Lei Guo⁵, Andrew McKenzie⁵, Chen Ming⁵, Xianxiao Zhou⁵, Minghui Wang⁵, Yotam Sagi⁶, Alan E. Renton⁴, Bianca T. Esposito⁴, Yong Kim⁶, Katherine R. Sadleir⁷, Ivy Trinh⁸, Robert A. Rissman⁸, Robert Vassar⁷, Bin Zhang⁵, Douglas S. Johnson⁹, Eliezer Masliah⁸, Paul Greengard^{6,ε}, Alison Goate^{4,5} and Yue-Ming Li^{1,2,3,*}

SUPPLEMENTARY INFORMATION

Supplementary Information Guide

Supplementary Figure 1: Gel Source Data.

Supplementary Table 1: List of human brain tissues used in Figure 4.

Supplementary Table 2: Spearman's correlation between the expression level of *IFITM3* and A β load.

Supplementary Table 3: Human IFITM3 SNP Genotypes.

Supplementary Table 4: Correlation between IFITM3 and cytokines in a large AD human dataset.

Supplementary Table 5: Correlation between IFITM3 and of type I IFN responsive genes in a large AD human dataset.